SCHEMBL5578142

SCHEMBL5578142

COc1ccc(Cn2cc(NC(=O)c3c(F)cccc3F)c(CO)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.47
RAB9A P51151 2/20 0.45
POLB P06746 1/20 0.44
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43
TUBB2A Q13885 1/20 0.43
TUBB8 Q3ZCM7 1/20 0.43
TUBA3E Q6PEY2 1/20 0.43
TUBA1A Q71U36 1/20 0.43
TUBA1C Q9BQE3 1/20 0.43
TUBB6 Q9BUF5 1/20 0.43
TUBB2B Q9BVA1 1/20 0.43
TUBB1 Q9H4B7 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578304 0.89 BRPF1 (0.46) BRPF1RAB9APOLBTUBB4ATUBB
SCHEMBL14511672 0.87 BRPF1 (0.46) BRPF1RAB9APOLBTUBB4ATUBB
SCHEMBL5578103 0.87 BRPF1 (0.46) BRPF1RAB9APOLBTUBB4ATUBB
SCHEMBL14511664 0.80 ADORA3 (0.43) BRPF1RAB9ACACNA1GCACNA1HCACNA1I
SCHEMBL5578064 0.77 ADORA3 (0.39) BRPF1LMNAMAPTKLKB1CACNA1G
SCHEMBL5578357 0.76 MAPT (0.39) BRPF1RAB9ALMNAMAPTKLKB1
SCHEMBL5578233 0.75 KMT2A (0.39) BRPF1RAB9APOLBLMNAMAPT
SCHEMBL5578146 0.73 LMNA (0.35) BRPF1RAB9ALMNAMAPTGAA
SCHEMBL5578287 0.72 MEN1 (0.44) KLKB1CACNA1GCACNA1HCACNA1I
SCHEMBL15622743 0.72 SMN1; SMN2 (0.45) RAB9AMAPTKLKB1CACNA1GCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
EP-1648449-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS Astex Therapeutics Limited (GB) 2006-04-26 EP disclosed
WO-2005002576-A2 IMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105900-A1 Pharmaceutical compounds AURKA, AURKC, CDK1 BRPF1 4778/4885RAB9A 4050/4885POLB 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.